

Your Vision, Our Future

Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2013

August 9, 2012 Yasuo Takeuchi Director, Senior Executive Managing Officer Group President of Group Management Office Olympus Corporation

I. Consolidated Financial Results and Business Overview for 1Q (Apr.-Jun.) of the FY Ending March 31, 2013



1Q of FY Ending March 2013 (1) Consolidated Financial Results

(Billions of yen)	March 2012 1Q (Apr - Jun)	March 2013 1Q (Apr - Jun)	YoY Change	YoY after adjusting FX impact
Net sales	198.6	189.5	-5%	-1%
Operating income (% to sales)	5.2 (2.6%)	2.1 (1.1%)	-60%	-10%
Ordinary income (% to sales)	0.9 (0%)	-0.2 (-)	-	
Net income (loss) (% to sales)	-1.4 (-)	-4.5 (-)	-	
[Foreign exchange rates and i	(Difference)			
¥/US\$	¥82	¥80	-¥2	
¥/Euro	¥117	¥103	-¥14	
Impact on net sales	-	-¥6.1 bil.		
Impact on operating income	-	-¥2.6 bil.		

[1Q Summary]

- ✓ Net sales and operating income dropped by 5% and 60% year on year respectively, mainly due to yen appreciation.
- ✓ After adjusting FX impact, net sales and operating income dropped by 1% and 10% year on year, respectively.
- ✓ 1Q net loss was ¥4.5 bil. primarily due to recording extraordinary loss of ¥1.8 bil.

OLYMPUS

1Q of FY Ending March 2013 (2) Results by Business Segment

•The Medical Business remained strong, which sales and profit grew


(B	illions of yen)	March 2012 1Q (Apr - Jun)	March 2013 1Q (Apr - Jun)	YoY Change	YoY after adjusting FX impact
Medical	Net sales	77.6	78.4	+1%	+6%
Medical	Op. income	10.9	12.4	+13%	+33%
Life Science &	Net sales	20.6	17.7	-14%	-10%
Industrial	Op. income	0.5	- 0.4	-	-
Imoging	Net sales	34.3	28.8	-16%	-11%
Imaging	Op. income	0.4	- 1.5	-	-
Information &	Net sales	52.6	53.9	+2%	+2%
Communication	Op. income	1.0	0.5	-46%	-46%
Othoro	Net sales	13.5	10.7	-20%	-20%
Others	Op. income	- 1.1	- 1.1	-	-
Elimination and	Net sales	-	-	-	-
corporate	Op. income	- 6.4	- 7.8	-	-
Consolidated Total	Net sales	198.6	189.5	-5%	-1%
	Op. income	5.2	2.1	-60%	-10%



1Q of FY Ending March 2013 (3) Medical Business


•Stable performance achieved mainly in Europe and Asia on actual basis excluding the impact of currency translation.

•New products (EXERA III and THUNDERBEAT) will likely to contribute to the business performance in or after 2Q of FY ending March 2013




1Q of FY Ending March 2013 (4) Life Science & Industrial Business

- Due to a reduction in capital investment in the private sector, both net sales and operating income decreased.
- New products (DSX series, IX3 series and IPLEX TX) gained high reputations and will likely to contribute to the business performance in or after 2Q.




1Q of FY Ending March 2013 (5) Imaging Business

- Under the shrinking of digital camera market, especially the market of low-end compact cameras, net sales and operating income decreased.
- Mirrorless SLR, centering on OM-D, sold well both in Japan and overseas (sales volume: +11%; net sales: +50%.)



Quarterly Performance in Imaging (1Q of Mar 2012 to 2Q of Mar 2013)


•Both net sales and operating income are improving steadily from the bottoming out in 4Q of FY ended March 2012.



1Q of FY Ending March 2013 (6) Net Sales by Region

(Billions of yen)

After adjusting for FX impact





Balance Sheet (End of June 2012)

(Billions of yer						ons of yen)	
	End March 2012	End June 2012	Change		End March 2012	End June 2012	Change
Current assets	526.6	503.9	- 22.6	Current liabilities	320.4	299.9	- 20.5
(Digital camera inventories)	(23.6)	(25.0)	(+1.4)				
Property, plant and equipment	127.8	125.6	- 2.2	Non-current liabilities	598.1	593.8	- 4.3
Intangible assets	197.1	187.1	- 10.1	(Incl. bonds/ long-term loans payable)	(530.3)	(528.6)	(- 1.7)
Investments and other assets	115.0	100.3	- 14.7	Net assets	48.0	23.2	- 24.8
			'	(Equity ratio)	(4.6%)	(2.2%)	
Total assets	966.5	916.9	- 49.6	Total liabilities and net assets	966.5	916.9	- 49.6

Interest-bearing debt : ¥638.4 billion(- ¥4.0 billion)

Net interest-bearing debt : ¥433.5 billion(- ¥8.9 billion)

OLYMPUS

Cash Flows (April - June)

(Billions of yen)

	March 2012 1Q (Apr - Jun)	March 2013 1Q (Apr - Jun)	Change
Net sales	198.6	189.5	- 9.0
Operating income	5.2	2.1	- 3.1
(%)	2.6%	1.1%	-
CF from operating activities	12.9	13.1	+ 0.1
CF from investing activities	- 9.1	- 8.4	+ 0.7
CF from financing activities	52.1	0.3	- 51.9
Cash flow	56.0	5.0	- 51.0
Free cash flow	3.9	4.7	+ 0.8
Cash and deposits	267.0	204.9	- 62.0

Depreciation and amortization	8.3	7.8	- 0.5
Amortization of goodwill	2.8	2.7	- 0.1
Capital expenditures	8.0	7.2	- 0.8

Note: The above figures are based on statements of cash flows



II. Forecasts for FY ending March 31, 2013



Forecasts of Consolidated Financial Results for FY ending March 2013

- Full-year forecasts for net sales and operating income are expected to increase by 8% and 41%, respectively, with a return to net income.
- Business operation to be executed according to the annual plan released in June.

(Billions of yen)	March 2013 1H (Apr - Sept) (Forecast)	YoY Change	March 2013 Full-year (Forecast)	YoY Change
Net sales	427.0	+3%	920.0	+8%
Operating income	22.0	+26%	50.0	+41%
(% to net sales)	(5.2%)		(5.4%)	
Ordinary income	7.4	-22%	21.0	+18%
(% to net sales)	(1.7%)		(2.3%)	
Net income	2.0	-	7.0	-
(% to net sales)	(0.5%)		(0.8%)	

Foreign exchange rates : $\frac{1000}{1000} = \frac{1000}{1000} = \frac{1000}{1000}$



Segment Forecasts for FY ending March 31, 2013

•Almost all the segments are expected to record year-on-year increases both in sales and income for full-year forecasts.

(Bil	lions of yen)	March 2013 1H (Apr - Sept) (Forecast)	YoY Change	March 2013 Full-year (Forecast)	YoY Change
Medical	Net sales	181.0	+11%	383.0	+10%
Weulcal	Op. income	38.0	+34%	75.0	+10%
Life Science &	Net sales	430	-4%	97.0	+5%
Industrial	Op. income	1.5	-57%	5.5	+1%
Imening	Net sales	64.0	-10%	149.0	+16%
Imaging	Op. income	-2.0	-	1.0	-
Information &	Net sales	114.0	+4%	237.0	+3%
Communication	Op. income	3.0	+9%	5.0	-6%
Others	Net sales	25.0	-2%	54.0	+10%
	Op. income	-3.5	-	-6.5	-
Elimination and corporate	Net sales	-	-	-	-
	Op. income	-15.0	-	-30.0	-
Consolidated	Net sales	427.0	+3%	920.0	+8%
Total	Op. income	22.0	+26%	50.0	+41%






Supplementary Materials




Depreciation and Amortization, Capital Expenditures






R&D Expenditures







Digital Cameras





Performance forecasts and other forward-looking statements in this presentation reflect judgments and assumptions based on information available at the time of writing. Because of the uncertainty inherent to judgments and assumptions, and because of the potential for future changes in business operations, conditions in Japan or overseas, or other factors, actual results, etc., may differ substantially from the targets stated.

